Bettina Löffler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bettina Löffler has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Christina Ehrhardt
Section of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Jena, Germany
2 shared publications - Josefine Schroeder
Section of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Hans Knoell-Str. 2, 07745 Jena, Germany
2 shared publications - Axel A. Brakhage
Department of Molecular and Applied Microbiology, Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI)
1 shared publication - Beatrice Engert
Inflamed pharma GmbH, Winzerlaer Str. 2, D-07745 Jena, Germany
1 shared publication - Clio Häring
Section of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, 07745 Jena, Germany
1 shared publication - Johannes Jungwirth
Section of Experimental Virology, Institute of Medical Microbiology, Center for Molecular Biomedicine (CMB), Jena University Hospital, Hans-Knoell-Str. 2, D-07745 Jena, Germany
1 shared publication
Latest Publications
- Open Access
- 24 November 2023
- Published by Elsevier in Microbes and Infection
- Vol. 26 (3) , 105264
The influenza A virus promotes fungal growth of Aspergillus fumigatus via direct interaction in vitro
- 24 November 2023
- Published by Elsevier in Microbes and Infection
- Vol. 26 (3) , 105264
Open AccessThe influenza A virus promotes fungal growth of Aspergillus fumigatus via direct interaction in vitro
- Open Access
- 26 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14584
The Local Anaesthetic Procaine Prodrugs ProcCluster® and Procaine Hydrochloride Impair SARS-CoV-2 Replication and Egress In Vitro
As vaccination efforts against SARS-CoV-2 progress in many countries, there is still an urgent need for efficient antiviral treatment strategies for those with severer disease courses, and lately, considerable efforts have been undertaken to repurpose existing drugs as antivirals. The local anaesthetic procaine has been investigated for antiviral properties against several viruses over the past decades. Here, we present data on the inhibitory effect of the procaine prodrugs ProcCluster® and procaine hydrochloride on SARS-CoV-2 infection in vitro. Both procaine prodrugs limit SARS-CoV-2 progeny virus titres as well as reduce interferon and cytokine responses in a proportional manner to the virus load. The addition of procaine during the early stages of the SARS-CoV-2 replication cycle in a cell culture first limits the production of subgenomic RNA transcripts, and later affects the replication of the viral genomic RNA. Interestingly, procaine additionally exerts a prominent effect on SARS-CoV-2 progeny virus release when added late during the replication cycle, when viral RNA production and protein production are already largely completed.
- 26 September 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (19) , 14584
Open AccessThe Local Anaesthetic Procaine Prodrugs ProcCluster® and Procaine Hydrochloride Impair SARS-CoV-2 Replication and Egress In Vitro
As vaccination efforts against SARS-CoV-2 progress in many countries, there is still an urgent need for efficient antiviral treatment strategies for those with severer disease courses, and lately, considerable efforts have been undertaken to repurpose existing drugs as antivirals. The local anaesthetic procaine has been investigated for antiviral properties against several viruses over the past decades. Here, we present data on the inhibitory effect of the procaine prodrugs ProcCluster® and procaine hydrochloride on SARS-CoV-2 infection in vitro. Both procaine prodrugs limit SARS-CoV-2 progeny virus titres as well as reduce interferon and cytokine responses in a proportional manner to the virus load. The addition of procaine during the early stages of the SARS-CoV-2 replication cycle in a cell culture first limits the production of subgenomic RNA transcripts, and later affects the replication of the viral genomic RNA. Interestingly, procaine additionally exerts a prominent effect on SARS-CoV-2 progeny virus release when added late during the replication cycle, when viral RNA production and protein production are already largely completed.